Skip to content
Screener

Tango Therapeutics TNGX Vopimetostat Direct Program Expenses-RD — Research And Development Expense

Other segment segments

Personnel-Related Expenses-RD
$12.93M-6.6%
Facilities And Other Related Expenses-RD
$4.34M-20.6%
TNG456Direct Program Expenses-RD
$2.06M+55.8%
TNG260Direct Program Expenses-RD
$2.01M+16.1%
Discovery Direct Program Expenses-RD
$1.87M-60.0%
TNG908Direct Program Expenses-RD
$581K-66.1%
TNG961Direct Program Expenses-RD
$408K-81.6%

Similar metrics at other companies

Scholar Rock logo
SRRKRD Expense Srk181 — Research And Development Expense
$9K-98.9%
Scholar Rock logo
SRRKRD Expense Srk439 — Research And Development Expense
$3.76M+46.0%
Rapport Therapeutics, Inc. logo
RAPPPreclinical Programs External Expenses — Research And Development Expense
$4.87M+3.1%
Beam Therapeutics logo
BEAMExternal Research And Development Expenses — Research And Development Expense
$30.08M-12.6%
MapLight Therapeutics, Inc. logo
MPLTPreclinical Program — Research And Development Expense
$5.52M-9.2%
Tyra Biosciences, Inc. logo
TYRAOther Development Programs — Research And Development Expense
$849K+65.2%

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.72B+570%
Enterprise value$4.59B+558%
P/S82.9×+53.9×

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-221656
Line itemOncology Segment / Three Months Ended March 31, 2026Oncology Segment / Three Months Ended March 31, 2025
Revenue—$5,392
Less:
vopimetostat direct program expenses - R&D9,3325,461
TNG456 direct program expenses - R&D2,0631,324
TNG260 direct program expenses - R&D2,0091,730
TNG961 direct program expenses - R&D4082,221
TNG908 direct program expenses* - R&D5811,712
Discovery direct program expenses - R&D1,8724,679

Item 1. Financial Statements.

FAQ

What is Tango Therapeutics's vopimetostat direct program expenses-rd — research and development expense?
Tango Therapeutics (TNGX) reported vopimetostat direct program expenses-rd — research and development expense of $9.33M in Q1 2026.
How has Tango Therapeutics's vopimetostat direct program expenses-rd — research and development expense changed year-over-year?
Tango Therapeutics's vopimetostat direct program expenses-rd — research and development expense increased by 70.9% year-over-year, from $5.46M to $9.33M.
What does vopimetostat direct program expenses-rd — research and development expense mean?
This metric represents the direct research and development costs specifically allocated to the Vopimetostat clinical program. It captures the investment required for preclinical studies, clinical trials, and manufacturing development associated with this specific therapeutic candidate. Tracking these costs allows investors to evaluate the capital intensity and progress of the company's lead precision oncology assets.

Ask your AI about Tango Therapeutics's vopimetostat direct program expenses-rd — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude